(PCVX) Vaxcyte - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US92243G1085
Stock:
Total Rating 25
Risk 68
Buy Signal -0.35
| Risk 5d forecast | |
|---|---|
| Volatility | 47.8% |
| Relative Tail Risk | -8.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | -40.78 |
| Character TTM | |
|---|---|
| Beta | 1.584 |
| Beta Downside | 3.402 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.22% |
| CAGR/Max DD | 0.18 |
Description: PCVX Vaxcyte
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA -5.51 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 > 3% & CFO -655.6m > Net Income -766.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.1m) vs 12m ago 10.78% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -20.13 > 6 (EBITDA TTM -781.8m / Interest Expense TTM -40.1m) |
Altman Z'' -7.17
| A: 0.47 (Total Current Assets 1.63b - Total Current Liabilities 205.8m) / Total Assets 3.05b |
| B: -0.71 (Retained Earnings -2.15b / Total Assets 3.05b) |
| C: -0.25 (EBIT TTM -806.7m / Avg Total Assets 3.28b) |
| D: -5.97 (Book Value of Equity -2.15b / Total Liabilities 360.5m) |
| Altman-Z'' Score: -7.17 = D |
Beneish M
| DSRI: none (Receivables 46.6m/20.7m, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.77 (AQ_t 0.30 / AQ_t-1 0.40) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: -0.04 (NI -766.6m - CFO -655.6m) / TA 3.05b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of PCVX shares?
As of March 04, 2026, the stock is trading at USD 59.82 with a total of 1,348,508 shares traded.
Over the past week, the price has changed by -2.49%, over one month by +7.34%, over three months by +25.41% and over the past year by -17.03%.
Over the past week, the price has changed by -2.49%, over one month by +7.34%, over three months by +25.41% and over the past year by -17.03%.
Is PCVX a buy, sell or hold?
Vaxcyte has received a consensus analysts rating of 4.90.
Therefore, it is recommended to buy PCVX.
- StrongBuy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PCVX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 109 | 82.2% |
| Analysts Target Price | 109 | 82.2% |
PCVX Fundamental Data Overview March 01, 2026
P/B = 2.9774
Revenue TTM = 0.0 USD
EBIT TTM = -806.7m USD
EBITDA TTM = -781.8m USD
Long Term Debt = 222.7m USD (estimated: total debt 228.8m - short term 6.12m)
Short Term Debt = 6.12m USD (from shortTermDebt, last quarter)
Debt = 228.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 54.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.63b USD (8.97b + Debt 228.8m - CCE 1.56b)
Interest Coverage Ratio = -20.13 (Ebit TTM -806.7m / Interest Expense TTM -40.1m)
EV/FCF = -11.40x (Enterprise Value 7.63b / FCF TTM -669.3m)
FCF Yield = -8.77% (FCF TTM -669.3m / Enterprise Value 7.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.51 (Enterprise Value 7.63b / Total Assets 3.05b)
Interest Expense / Debt = 4.69% (Interest Expense 10.7m / Debt 228.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.91 (Total Current Assets 1.63b / Total Current Liabilities 205.8m)
Debt / Equity = 0.09 (Debt 228.8m / totalStockholderEquity, last quarter 2.69b)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 54.9m / EBITDA -781.8m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 54.9m / FCF TTM -669.3m)
Total Stockholder Equity = 2.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.38% (Net Income -766.6m / Total Assets 3.05b)
RoE = -25.88% (Net Income TTM -766.6m / Total Stockholder Equity 2.96b)
RoCE = -25.33% (EBIT -806.7m / Capital Employed (Equity 2.96b + L.T.Debt 222.7m))
RoIC = -20.86% (negative operating profit) (NOPAT -637.3m / Invested Capital 3.05b)
WACC = 11.55% (E(8.97b)/V(9.19b) * Re(11.75%) + D(228.8m)/V(9.19b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.16%
[DCF] Fair Price = unknown (Cash Flow -669.3m)
EPS Correlation: -64.67 | EPS CAGR: -46.64% | SUE: -0.97 | # QB: 0
Revenue Correlation: -0.00 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.85 | Chg7d=-0.253 | Chg30d=-0.253 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=-7.39 | Chg7d=-1.210 | Chg30d=-1.172 | Revisions Net=-2 | Growth EPS=-31.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.29 | Chg7d=-0.140 | Chg30d=-0.146 | Revisions Net=-2 | Growth EPS=+1.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Current Year)
Revenue TTM = 0.0 USD
EBIT TTM = -806.7m USD
EBITDA TTM = -781.8m USD
Long Term Debt = 222.7m USD (estimated: total debt 228.8m - short term 6.12m)
Short Term Debt = 6.12m USD (from shortTermDebt, last quarter)
Debt = 228.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 54.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.63b USD (8.97b + Debt 228.8m - CCE 1.56b)
Interest Coverage Ratio = -20.13 (Ebit TTM -806.7m / Interest Expense TTM -40.1m)
EV/FCF = -11.40x (Enterprise Value 7.63b / FCF TTM -669.3m)
FCF Yield = -8.77% (FCF TTM -669.3m / Enterprise Value 7.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.51 (Enterprise Value 7.63b / Total Assets 3.05b)
Interest Expense / Debt = 4.69% (Interest Expense 10.7m / Debt 228.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.91 (Total Current Assets 1.63b / Total Current Liabilities 205.8m)
Debt / Equity = 0.09 (Debt 228.8m / totalStockholderEquity, last quarter 2.69b)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 54.9m / EBITDA -781.8m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 54.9m / FCF TTM -669.3m)
Total Stockholder Equity = 2.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.38% (Net Income -766.6m / Total Assets 3.05b)
RoE = -25.88% (Net Income TTM -766.6m / Total Stockholder Equity 2.96b)
RoCE = -25.33% (EBIT -806.7m / Capital Employed (Equity 2.96b + L.T.Debt 222.7m))
RoIC = -20.86% (negative operating profit) (NOPAT -637.3m / Invested Capital 3.05b)
WACC = 11.55% (E(8.97b)/V(9.19b) * Re(11.75%) + D(228.8m)/V(9.19b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.16%
[DCF] Fair Price = unknown (Cash Flow -669.3m)
EPS Correlation: -64.67 | EPS CAGR: -46.64% | SUE: -0.97 | # QB: 0
Revenue Correlation: -0.00 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.85 | Chg7d=-0.253 | Chg30d=-0.253 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=-7.39 | Chg7d=-1.210 | Chg30d=-1.172 | Revisions Net=-2 | Growth EPS=-31.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.29 | Chg7d=-0.140 | Chg30d=-0.146 | Revisions Net=-2 | Growth EPS=+1.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Current Year)